(BNR) Burning Rock Biotech Limited Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BNR) Burning Rock Biotech Limited Complete Analysis Pack
Burning Rock Biotech’s Business Model, Simplified
Discover how Burning Rock Biotech Limited creates value through precision oncology testing, strong R&D, and strategic partnerships. This Business Model Canvas breaks down the company’s customer segments, revenue streams, key resources, and cost drivers in a clear, practical format. Get the full version to unlock deeper strategic insights and decision-making value.
Partnerships
Myriad Genetics China license
Burning Rock Biotech holds the China development and commercialization license for Myriad myChoice tumor testing, adding homologous recombination deficiency testing to its oncology menu. The deal supports local sales in China and broadens Burning Rock's addressable market in precision oncology, where HRD testing is used to guide PARP inhibitor therapy.
Oncocyte DetermaRx China license
Burning Rock Biotech Limited licenses Oncocyte's DetermaRx in China, adding a prognostic test for early-stage lung cancer that stratifies recurrence risk after surgery. This deepens its lung cancer offer beyond mutation testing, in a market where lung cancer still causes about 1.06 million new cases and 733,300 deaths in China each year.
Pharma collaboration network
Burning Rock Biotech Limited works with 8 named pharma partners: AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA. These ties support clinical trials, translational research, and broader real-world evidence generation for its assays.
Hospital and cancer center partners
Burning Rock Biotech Limited depends on hospital and cancer center partners for in-hospital deployment, sample collection, and physician access, which puts its tests into routine oncology decisions. In 2025, this channel still anchored clinical adoption because oncologists need on-site workflows to order, collect, and act on results fast.
- Drives test adoption
- Enables sample collection
- Reaches oncologists directly
- Supports routine care use
NGS ecosystem partners
Burning Rock Biotech Limited depends on sequencing, laboratory, and bioinformatics partners to keep reagent supply, platform access, and test workflows stable. For NGS diagnostics, these links are core to turnaround time, assay reliability, and scaling across clinical sites.
In FY2025, this partner layer remained critical because one break in supply or software support can slow sample processing and disrupt test output. In plain terms: no partner chain, no steady NGS service.
- Reagents secure assay continuity
- Platforms enable sequencing access
- Bioinformatics supports result accuracy
Burning Rock’s Partner Network Keeps Assay Volume and Sequencing Stable
Burning Rock Biotech Limited relies on pharma, hospital, and platform partners to drive assay uptake, local clinical access, and test continuity. In FY2025, its named pharma links included AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA, while hospital channels and lab vendors kept sample flow and NGS output stable.
| Partner layer | FY2025 role |
|---|---|
| Pharma | 8 named partners |
| Hospitals | Sample collection |
| Lab tech | Sequencing continuity |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Burning Rock Biotech Limited, mapping its oncology diagnostics strategy, customers, channels, revenue, and key capabilities.
Customizable Excel Spreadsheet
Clarifies Burning Rock Biotech Limited’s key pain points and solutions in one editable snapshot.
Reference Sources
Lists the key sources behind Burning Rock Biotech Limited’s analysis, making the research credible, traceable, and easier to use in decisions.
Activities
NGS assay development
Burning Rock Biotech Limited uses next-generation sequencing to build tissue and liquid biopsy cancer tests, with assay work centered on panel design, analytical validation, and clinical utility. Its liquid biopsy programs target low-frequency variants, where NGS can detect changes at around 0.1% variant allele fraction, which is key for cancer monitoring and treatment selection.
Central laboratory testing
Burning Rock Biotech Limited runs central laboratory testing for oncology, where samples are processed and interpreted through its own workflow. This model gives the Company national reach across China and, in its latest reported results, helped support a large-scale testing base with 100,000+ tests performed in a year.
In-hospital test deployment
Burning Rock Biotech Limited's in-hospital test deployment keeps molecular diagnostics inside hospital workflows, so physicians can order and act on results faster. This model fits routine care, especially in oncology, and supports repeat testing rather than one-off send-out work.
Pharma R and D services
Burning Rock Biotech Limited monetizes its assay and data platform through pharma R and D services for clinical trials, biomarker studies, and companion diagnostic work. This activity turns its sequencing and analytics base into partner revenue, but the latest 2025/2026 segment figures were not available in the source material I used.
- Supports trial design and patient selection
- Drives biomarker discovery and validation
- Enables companion diagnostic development
- Converts assay data into partner revenue
Bioinformatics reporting
Burning Rock Biotech Limited turns sequencing output into clinical reports for therapy selection, so interpretation is the core of its diagnostic value. Data analysis and report generation are the two main operating tasks that convert raw reads into usable treatment guidance.
- Interpret variants for therapy choice
- Analyze data for clinical use
- Generate reports fast and accurately
100K+ Tests, 0.1% VAF Liquid Biopsy Powering Oncology
Burning Rock Biotech Limited's key activities are assay development, clinical validation, central lab testing, in-hospital deployment, and biomarker services for pharma partners. In its latest reported year, the Company supported 100,000+ tests, while its liquid biopsy work targets variants down to about 0.1% VAF for oncology monitoring and therapy selection.
| Activity | Data point |
|---|---|
| Testing volume | 100,000+ tests/year |
| Liquid biopsy sensitivity | ~0.1% VAF |
| Core work | Assay, validation, reporting |
Full Document Unlocks After Purchase
Business Model Canvas
This preview of the Burning Rock Biotech Limited Business Model Canvas is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a direct preview of the final file, complete in the same format and structure. Once purchased, you’ll download this same professional document, ready to use, edit, and present.
Resources
NGS test portfolio
Burning Rock Biotech Limited’s NGS test portfolio is its core commercial asset, covering multiple cancer types with OncoCompass IO, OncoScreen IO, OncoCompass Target, ColonCore, and ParpMatch. In 2025, the Company reported a total revenue of RMB 692.6 million, and this test portfolio remains the main driver of that base.
Central lab and in-hospital infrastructure
Burning Rock Biotech Limited relies on central labs and in-hospital infrastructure to process tissue and liquid biopsy samples, which keeps testing standardized and scalable. This setup also lets the Company deploy services inside hospitals, supporting faster turnaround and broader clinical reach.
Licensed test rights in China
Burning Rock Biotech Limited holds China rights to two licensed tests, Myriad myChoice tumor testing and Oncocyte DetermaRx. These licenses add differentiated products without building them from scratch, which cuts development time and speeds market entry in a country with over 1.4 billion people.
Clinical and genomic data
Burning Rock Biotech Limited turns clinical and cancer genomic data from testing and research collaborations into a core input for assay interpretation, refinement, and product development. Its 2025 filings showed total revenue of US$76.6 million, with data-rich testing workflows helping feed both clinical use and research partnerships.
- Supports assay refinement
- Improves variant interpretation
- Feeds research partnerships
- Drives product development
Oncology and bioinformatics expertise
Burning Rock Biotech Limited relies on molecular-diagnostics, oncology, and bioinformatics specialists to validate panels and convert sequencing data into clinically useful reports. This human capital is the core input behind test design, variant interpretation, and physician-facing reporting, and it stays central as the company scales its platform in 2025/2026.
- Validates panels for clinical use
- Interprets complex genomic data
- Produces actionable oncology reports
Burning Rock’s NGS Portfolio Powers 2025 Revenue
Burning Rock Biotech Limited’s key resources are its NGS test menu, licensed assays, and China lab network, which together supported RMB 692.6 million in 2025 revenue and US$76.6 million in reported 2025 revenue. Its clinical genomic data and oncology specialists turn sequencing into usable reports and help refine products.
| Key resource | 2025 fact |
|---|---|
| NGS test portfolio | Main revenue driver |
| Licensed tests | 2 China rights |
| Reported revenue | US$76.6 million |
Value Propositions
Therapy selection for cancer patients
Burning Rock Biotech Limited helps guide oncology treatment choice by identifying biomarkers that support targeted therapy and immunotherapy decisions. This is its core clinical value proposition, because the tests help clinicians match the right therapy to the right cancer patient.
Tissue and liquid biopsy options
Burning Rock Biotech Limited tests 2 sample types, tissue and liquid biopsy, so clinicians can choose based on sample access and disease stage. In 2025/2026, that broader fit supports use across more patients, from tissue-rich diagnosis to blood-based monitoring when tissue is scarce.
Pan-cancer and indication-specific panels
Burning Rock Biotech Limited offers both pan-cancer and indication-specific panels, with products like OncoScreen IO for tissue and OncoCompass Target for NSCLC. This mix lets the Company cover broad tumor profiling and narrower clinical use cases in one portfolio, which supports more test volume across oncology workflows.
Prognostic and risk stratification insights
Burning Rock Biotech Limited’s value goes beyond mutation calls: ColonCore, DetermaRx, and ParpMatch add prognostic and risk-stratification signals that help guide who needs closer follow-up, adjuvant therapy, or different treatment paths. That broadens the clinical use of its tests from therapy matching to outcome and recurrence risk insight.
- ColonCore: prognosis support
- DetermaRx: recurrence-risk stratification
- ParpMatch: treatment stratification
China-localized access to advanced assays
Licensed products and local commercialization let Burning Rock Biotech Limited bring advanced molecular diagnostics into China without forcing patients into cross-border testing routes. That fits local clinical workflows, shortens turnaround time, and makes assays easier to adopt in hospitals and labs.
- Local access cuts cross-border testing delays.
- Fits China hospital and lab workflows.
- Supports faster clinical use of advanced assays.
Precision Oncology Profiling for Better Treatment Matching
Burning Rock Biotech Limited’s value proposition is precise oncology profiling that helps match treatment to the right patient using tissue and liquid biopsy. Its portfolio spans broad and indication-specific assays, plus prognostic tools, so clinicians can use one platform across diagnosis, therapy selection, and recurrence-risk decisions.
| 2025/2026 signal | Why it matters |
|---|---|
| 2 sample types | Broader patient access |
| Pan-cancer + NSCLC panels | Wider clinical use |
| Prognostic add-ons | Risk stratification |
Customer Relationships
Clinical decision support partnership
Burning Rock Biotech Limited keeps a high-touch B2B2C link with oncologists and hospital teams, focusing on test interpretation and treatment selection. This model fits its oncology NGS workflow, where clinical support helps turn complex results into faster, more precise care decisions.
Long-term pharma collaboration
Pharmaceutical partners use Burning Rock Biotech Limited for trial support and biomarker work, and the work is usually project based but often repeats across multiple studies. These ties last when the company proves strong scientific credibility and clean data quality, since that lowers trial risk and helps partners trust each next study.
Hospital implementation support
Burning Rock Biotech Limited’s in-hospital model depends on hands-on implementation support: staff training, workflow fit, and quick troubleshooting so clinicians can use the test inside daily care without disruption. Ongoing support keeps adoption from fading after launch and helps sustain utilization across hospital accounts.
Central lab service relationship
Burning Rock Biotech Limited’s central lab service relationship runs on repeat sample processing and report delivery, not one-off sales. Service reliability matters most because clients depend on fast, accurate results and consistent turnaround; this makes the relationship sticky and operationally intensive.
- Repeat testing builds recurring demand.
- Report speed shapes client trust.
- Quality control protects retention.
Technical and medical affairs engagement
Burning Rock Biotech Limited keeps tight customer ties through medical affairs and technical teams that work with clinicians and research users on test use, result reading, and case follow-up. This direct support matters in molecular diagnostics, where trust depends on clear evidence and fast answers; in 2025, Burning Rock still tied commercial adoption to clinical education and technical service across oncology testing.
- Explain test utility clearly
- Support result interpretation fast
- Build clinician trust through contact
Burning Rock’s Growth Runs on High-Touch Clinical Trust
Burning Rock Biotech Limited’s customer relationships are built on close clinical and technical support, not one-time sales. In 2025, that meant oncologists, hospitals, and pharma partners relied on its staff for test use, result reading, and trial support, so trust, speed, and data quality stayed central.
| Customer | Relationship | Driver |
|---|---|---|
| Hospitals | High-touch | Training, workflow fit |
| Pharma | Project-based repeat | Biomarkers, trial support |
| Central lab | Recurring service | Fast, accurate reporting |
Channels
Central laboratory ordering
Burning Rock Biotech Limited routes patient samples through its central laboratory ordering channel, making molecular testing a direct service instead of a hospital-owned assay. This model lets the company reach sites nationwide without each hospital building the test itself, which keeps access broad and operating costs lower.
Hospital-based deployment
Hospital-based deployment puts Burning Rock Biotech Limited inside clinician workflows, so testing starts closer to the point of care and fits routine oncology care. This channel matters because hospital-led cancer care still handles most first-line diagnosis and treatment decisions, which makes in-hospital ordering and reporting the fastest route to repeat use.
Direct pharma contracts
Burning Rock Biotech Limited serves pharmaceutical and biotech clients through direct R&D contracts for trials, biomarker studies, and joint research work. These deals are a core B2B channel, often running 1–3 years and tying revenue to recurring project milestones rather than one-off sales.
Licensed product commercialization
Burning Rock Biotech Limited uses licensed product commercialization to bring assays like myChoice and DetermaRx into China through commercialization agreements. With local rights to distribute and promote these tests, the Company widens its channel reach beyond its own portfolio and taps partner products already validated in market use.
- Local China rights expand distribution
- Partner assays add commercial reach
- Supports broader oncology access
Medical and sales outreach
Burning Rock Biotech Limited depends on direct medical and sales outreach to hospitals, physicians, and research teams to explain complex liquid biopsy and tumor profiling tests, build trust, and turn interest into orders. In 2025, this channel is critical because complex diagnostics still need hands-on education before adoption.
- Educates clinicians fast
- Converts demand into use
- Supports complex test adoption
Burning Rock’s Hands-On Sales Model Drives Hospital and Pharma Growth
Burning Rock Biotech Limited reaches hospitals, labs, and pharma clients through direct ordering, hospital deployment, and R&D contracts, with licensed products widening access in China. Its sales motion is still hands-on: complex oncology tests need clinician education, and pharma projects often run 1–3 years.
| Channel | Role |
|---|---|
| Hospitals | Point-of-care ordering |
| Pharma R&D | Trial and biomarker revenue |
Customer Segments
Hospitals and cancer centers
Hospitals and cancer centers are Burning Rock Biotech Limited"s core customers for in-hospital and central lab testing, because they need molecular diagnostics to guide oncology care. Chinese hospitals are the main institutional buyers, and Burning Rock"s latest filings show this group remains central to clinical testing demand.
Oncologists and pathology teams
Oncologists and pathology teams are the main clinical users of Burning Rock Biotech Limited’s test results; they use them to choose therapies, refine diagnoses, and monitor how patients respond. Even when the hospital pays, their buy-in drives repeat testing and keeps the product in the care path.
Pharmaceutical and biotech companies
Pharmaceutical and biotech companies are a core customer segment for Burning Rock Biotech Limited: drug developers buy biomarker services, assay support, and trial testing for Phase I-III clinical studies and translational research. This B2B demand is central to pharma R&D, where even one companion diagnostic program can span multiple study sites and patient cohorts.
Cancer patients with solid tumors
Cancer patients with solid tumors are the end users, usually reached through physician referral. Burning Rock Biotech Limited focuses on lung, gastrointestinal, breast, ovarian, pancreatic, bladder, and related cancers; solid tumors make up most of the world’s 20 million new cancer cases each year, and testing helps match therapy to tumor genetics.
- Physician-referred end users
- Solid tumors across key cancer types
- Guides therapy choice
Indication focused patient groups
Burning Rock Biotech Limited’s customer segments are indication-based patient groups, with products built for NSCLC, gastrointestinal cancers, and HRD-linked cases. DetermaRx is aimed at early-stage lung cancer risk stratification, a niche that improves product-market fit by matching tests to specific clinical decisions; NSCLC still makes up about 85% of lung cancer cases.
- NSCLC: early-stage risk stratification
- GI cancers: broad molecular testing use
- HRD cases: therapy-guiding patient group
Burning Rock’s Core Demand: China, Solid Tumors, and Clinical Testing
Burning Rock Biotech Limited serves three main customer groups: hospitals and cancer centers, oncologists/pathology teams, and pharma or biotech firms. Its strongest demand sits in China and in solid-tumor care, especially NSCLC, GI, and HRD-linked cases; solid tumors account for about 20 million new cancer cases a year worldwide.
| Segment | Use |
|---|---|
| Hospitals | Clinical testing |
| Pharma | Trial biomarker support |
Cost Structure
R and D spending
R and D is a structural cost for Burning Rock Biotech Limited because it must fund assay design, biomarker research, and clinical validation before any test can scale. In diagnostics, these spend items are not optional: they drive evidence generation, regulatory support, and product credibility.
Laboratory operations
Laboratory operations are a core cost driver for Burning Rock Biotech Limited: every test needs trained staff, diagnostic equipment, quality control, and consumables, while both central-lab and in-hospital workflows consume fixed and variable resources. These costs rise with sample volume, so higher testing throughput can lift operating efficiency only if utilization stays high.
Bioinformatics and data processing
Bioinformatics and data processing are a recurring cost for Burning Rock Biotech Limited because each NGS test needs compute, storage, and expert review before a report is issued; a single whole-genome sample can generate about 100 GB of raw data. With China cancer testing demand still rising and Burning Rock Biotech Limited reporting FY2025 losses in its latest filings, this is a core operating expense.
Sales, medical affairs, and administration
Burning Rock Biotech Limited keeps spending on sales, medical affairs, and administration to win hospital accounts, support pharma partners, and stay compliant in a tightly regulated healthcare market. These functions matter because the business depends on trust, governance, and field support as it scales its oncology testing and biopharma services.
- Hospital and pharma selling costs
- Medical affairs support adoption
- Admin covers compliance and finance
- High fixed cost in regulated care
Licensing and collaboration costs
Burning Rock Biotech Limited's licensing and collaboration costs come from licensed products from Myriad Genetics and Oncocyte, plus pharma-partner projects and contract work. These payments help expand market access and bring in outside innovation, but they also add fixed and variable deal costs to the model.
- Licenses from Myriad Genetics and Oncocyte
- Pharma project and contract costs
- Supports market access and external innovation
Burning Rock’s High Fixed Costs Make Scale the Margin Key
Burning Rock Biotech Limited’s cost base is led by R&D, lab operations, data processing, and SG&A, plus licensing and pharma project fees. These are mostly fixed or semi-fixed, so margin gains depend on high test volume and tight lab use. One whole-genome sample can generate about 100 GB of raw data.
| Cost item | Key driver | Data point |
|---|---|---|
| R&D | Assays, biomarkers, validation | Pre-scale spend |
| Bioinformatics | Compute, storage, review | ~100 GB/sample |
Revenue Streams
Diagnostic test sales
Burning Rock Biotech Limited earns most of its revenue from diagnostic test sales, mainly OncoCompass IO and OncoScreen IO, which use tissue and liquid biopsy samples. This core stream generated most of the company’s operating income in FY2025, reinforcing diagnostics as the main business driver.
Central laboratory service fees
Burning Rock Biotech Limited earns central laboratory service fees by processing clinical samples for oncology testing, turning high-volume molecular diagnostics into recurring service revenue. The stream stays tied to routine cancer care, where every extra sample adds revenue with little change in fixed lab cost.
In-hospital business revenue
Burning Rock Biotech Limited's in-hospital business revenue comes from deploying tests inside hospitals, so each new site can drive repeat testing and recurring revenue as clinical adoption grows. This model also keeps the company close to physicians and patients, which helps speed use in routine care.
Pharma research and trial fees
Drug developers pay Burning Rock Biotech Limited for biomarker studies, clinical trial support, and research services, so this revenue stream sits outside routine diagnostics. In 2025, these contracts often ran across multiple projects and partners, which made them a steadier non-diagnostic income source than one-off testing.
- Biomarker studies for drug makers
- Trial support across multiple sites
- Research fees add non-diagnostic revenue
Licensing and commercialization income
Burning Rock Biotech Limited monetizes licensing by holding China commercialization rights and earning income from third-party products like Myriad myChoice and DetermaRx. This adds revenue without carrying the full cost and risk of in-house product development, so it can scale faster with lower capital burn.
China rights drive local monetization.
Myriad myChoice shows the model.
DetermaRx shows the model.
Licensing adds revenue, not full R&D.
Burning Rock’s FY2025 Revenue Stays Driven by Diagnostics
In FY2025, Burning Rock Biotech Limited’s revenue still came mainly from diagnostics, with test sales and central lab services as the core cash engine. In-hospital deployment, pharma biomarker work, and licensing of China rights added lower-risk, recurring income outside core testing.
| Stream | FY2025 role |
|---|---|
| Test sales | Main revenue driver |
| Central lab | Recurring sample fees |
| In-hospital | Site-based repeat sales |
| Pharma services | Multi-project fees |
| Licensing | China rights income |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.